Skip to main content

Table 1 HPV screening activity and test results by sociodemographic and programmatic characteristics among women screened for cervical cancer in Nicaragua in 2017

From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment

 TotalHPV Positive
N%NPrevalence % (95% CI)
Total44,635100677615.2 (14.9–15.5)
Department
 Carazo12,26127.5196216.0 (15.4–16.7)
 Chinandega21,33347.8302814.2 (13.7–14.7)
 Chontales11,04124.7178616.2 (15.5–16.9)
Age, years
Mean (SE)40.8 (8.6)N/A39.5 (8.5)N/A
Median (IQR)39.0 (33–47)N/A37.0 (20–71)N/A
In target age range (30–59 years)44,22299.1668198.6
Out of target age range3760.8911.3
  < 25390.09923.1 (12.4–39.0)
  25–291830.44725.7 (19.9–32.5)
  30–3413,25529.7245618.5 (17.9–19.2)
  35–39948521.3145915.4 (14.7–16.1)
  40–44720016.1101114.0 (13.3–14.9)
  45–49574412.971512.5 (11.6–13.3)
  50–54470010.556212.0 (11.1–12.9)
  55–5938388.647812.5 (11.4–13.5)
  60+1540.33522.7 (16.8–30.0)
  Missing370.08410.8 (4.1–25.8)
HPV Screening Method
 Self-collected43,10596.6657815.3 (14.9–15.6)
 Provider-collecteda6371.411217.6 (14.8–20.7)
 Unknown8932.0869.6 (7.9–11.7)
  1. Abbreviations: HPV Human papillomavirus, SE standard error, IQR Interquartile range, CI confidence interval
  2. a133 women were screened by both modalities; these women have been included in the provider-collected category, as there was generally either a real or perceived problem with the self-collected sample that required a provider to recollect the sample, and this provider-collected sample was used for HPV testing